JPMorgan Chase & Co. lifted its holdings in Recro Pharma Inc (NASDAQ:REPH) by 183.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,784 shares of the specialty pharmaceutical company’s stock after buying an additional 14,098 shares during the period. JPMorgan Chase & Co. owned about 0.11% of Recro Pharma worth $197,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Teachers Advisors LLC acquired a new stake in shares of Recro Pharma in the second quarter worth $162,000. California State Teachers Retirement System acquired a new stake in shares of Recro Pharma in the second quarter worth $169,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Recro Pharma in the second quarter worth $215,000. TIAA CREF Investment Management LLC acquired a new stake in shares of Recro Pharma in the second quarter worth $249,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Recro Pharma by 182.7% in the second quarter. Bank of New York Mellon Corp now owns 50,532 shares of the specialty pharmaceutical company’s stock worth $355,000 after buying an additional 32,655 shares during the period. 61.55% of the stock is owned by institutional investors and hedge funds.
Several analysts have recently commented on the company. Zacks Investment Research cut Recro Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recro Pharma in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Recro Pharma has an average rating of “Hold” and an average target price of $11.65.
Shares of Recro Pharma Inc (REPH) opened at $8.93 on Friday. Recro Pharma Inc has a 12-month low of $5.81 and a 12-month high of $10.59. The company has a quick ratio of 1.35, a current ratio of 1.59 and a debt-to-equity ratio of 0.50.
Recro Pharma (NASDAQ:REPH) last released its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.27. Recro Pharma had a negative return on equity of 60.01% and a negative net margin of 51.88%. sell-side analysts predict that Recro Pharma Inc will post -2.14 earnings per share for the current fiscal year.
Recro Pharma Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Want to see what other hedge funds are holding REPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recro Pharma Inc (NASDAQ:REPH).
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.